Earnings Call Summary | Gilead Sciences(GILD.US) Q1 2025 Earnings Conference

moomoo AI12minutes ago · Conference Call

Gilead Sciences Highlights Potential FDA Approval for Lenacapavir in June 2025

Seeking Alpha16minutes ago

Shares of T-Mobile US Slide After Postpaid Phone Adds Come Below Expectations

Seeking Alpha17:23 ET

Gilead Sciences in Charts: Revenue From HIV Product Sales Grows Most Among Segments in Q1

Seeking Alpha17:16 ET

Gilead Sciences Non-GAAP EPS of $1.81 Beats by $0.04, Revenue of $6.67B Misses by $140M

Seeking Alpha16:03 ET

Breaking Down AT&T: 16 Analysts Share Their Views

Benzinga16:00 ET